Business context and reporting period
The supplied filing is NanoAntibiotics, Inc.’s Form 10-K for the fiscal year ended June 30, 2014—not a BioVie Inc. filing or a filing for “2013 Q4.” Confirm the issuer and reporting period before relying on this summary. NanoAntibiotics describes itself as an early-stage biotechnology company developing efflux-pump inhibitors and nanoantibiotics for drug-resistant bacterial infections. Its candidates had only been tested in cell-based assays; animal and human testing had not begun.
Financial performance, liquidity and capital
| Metric | Year ended June 30, 2014 |
|---|---|
| Revenue | $0 |
| Operating expenses | $322,385, including $49,419 of R&D |
| Net loss | $321,896; loss per share reported as $0.00 |
| Cash from operating activities | $(172,832) |
| Cash at year-end | $332,864 |
| Current liabilities | $161,475, entirely accrued payroll |
| Total stockholders’ equity | $171,389 |
There was no reported debt. The balance sheet lists only cash as an asset. Gross margin is not meaningful because the company had no sales. The prior comparison covers only the period from incorporation on April 10, 2013 through June 30, 2013, when the net loss was $17,510; it is not a comparable full fiscal year. Cash decreased from $505,696 at June 30, 2013. The filing reports no investing or financing cash flows during fiscal 2014.
Material changes and unusual items
- Operating expenses rose to $322,385 from $17,515 in the short 2013 inception period; fiscal 2014 included $161,475 payroll expense and $85,602 professional fees.
- Cash fell by $172,832 during fiscal 2014. Accrued payroll of $161,475 was a significant year-end liability.
- The company issued 150,000 shares for scientific advisory services, valued at $15,000; $2,589 was expensed and the unamortized amount was recorded as prepaid services.
- Related-party issuances included 19 million shares to a director/officer and 15 million shares to a director/officer, each at $0.0001 per share. Separately, the filing describes a $500,000 private stock issuance in the 2013 period.
- Rights, formulations, studies and data were assigned to the company by Kard and President Rajah Menon. The company recorded the transferred rights at zero historical cost.
Outlook, risks and contingencies
Management estimated approximately $1 million in funding was needed to meet its next-12-month plan: $775,000 for R&D, $100,000 for overhead, $75,000 for capital costs and $150,000 for staffing. Planned R&D included approximately $375,000 for efflux-pump inhibitors and $400,000 for nanoantibiotics. The filing says available cash was insufficient for the plan and substantial doubt existed about the company’s ability to continue as a going concern. Management proposed seeking equity or debt financing, licensing or collaboration arrangements, but reported no committed financing.
- Development remained preclinical: candidates had not undergone animal efficacy, pharmacokinetic, or toxicity testing, and no patent applications had yet been filed.
- Management reported preliminary in-vitro dye-retention results in Staphylococcus epidermidis, but said it had not yet achieved an effective and safe efflux-pump blocker. These results do not establish efficacy or safety.
- Material risks include failure to raise capital, scientific and regulatory setbacks, dependence on third parties, limited staff and drug-development experience, competition, and lack of product-liability insurance.
- Disclosure controls and internal control over financial reporting were deemed ineffective. Management cited a lack of formalized controls and segregation of duties and the absence of an independent audit committee chair.
- The company had a five-year office lease with aggregate payments of $21,420 and a CEO/CFO employment agreement at $150,000 annual salary, effective July 1, 2013 through June 30, 2015.
- The filing reports no material legal proceedings and no material off-balance-sheet arrangements.
Most important facts to verify
- Issuer identity and period: the supplied filing names NanoAntibiotics, Inc. and reports fiscal 2014, despite the request metadata naming BioVie Inc. and 2013 Q4.
- Current financing, cash runway, and status of any funding raised after June 30, 2014; the filing states the company lacked funds for its planned next-12-month activities.
- Whether the accrued CEO/CFO payroll was paid, and the terms and approval of the related-party share issuances and asset transfer.
- Subsequent scientific results, animal studies, patent filings, regulatory progress, and whether any candidate advanced beyond cell-based testing.
- Whether the company remediated the disclosed material weaknesses in financial reporting controls.